TB-500 - Research Profile & Reviews

Research Overview

TB-500 is a synthetic version of the active region of Thymosin Beta-4 (Tβ4), a naturally occurring 43-amino-acid peptide present in virtually all human and animal cells. Thymosin Beta-4 is the primary G-actin sequestering protein in the body and plays critical roles in cell migration, blood vessel formation, and wound healing.

The peptide's primary mechanism involves upregulation of actin, a cell-building protein essential for tissue repair and cell migration. By promoting actin polymerization, TB-500 facilitates the migration of endothelial cells and keratinocytes to sites of injury, accelerating wound closure and tissue regeneration. It also promotes angiogenesis (new blood vessel formation) and reduces inflammation by downregulating inflammatory cytokines.

Research has demonstrated TB-500's efficacy in promoting healing of skin wounds, corneal injuries, cardiac tissue damage, and musculoskeletal injuries. Studies have shown accelerated wound healing, reduced scar formation, and improved functional recovery following various types of tissue damage. In cardiac research, Thymosin Beta-4 has shown the ability to activate cardiac progenitor cells and promote repair following myocardial infarction. Its systemic mobility through tissues gives it an advantage in reaching injury sites throughout the body.

Documented Research Effects

Recovery Joint Health Muscle Growth Skin Health

Dosage & Protocol

Typical Dose Range

2000 – 5000

mcg per dose

Frequency

2x weekly (loading), 1x weekly (maintenance)

Cycle Length

4-12 weeks

Common Vial Sizes

2 5 10

Calculate exact draw volumes and reconstitution steps.

Use Calculator

Dosage information is for research reference only. Always follow established research protocols. Not medical advice.

Storage & Handling

Lyophilized Powder

Temperature -20°C

Shelf Life 2+ years

Reconstituted Solution

Temperature 2-8°C

Shelf Life 4-6 weeks

Frequently Asked Questions

The typical TB-500 protocol involves a loading phase of 4-8 weeks at 2-5 mg administered twice weekly, followed by a maintenance phase of 2-5 mg once weekly or biweekly. Total loading phase doses generally range from 16-40 mg before transitioning to maintenance.

Yes, TB-500 and BPC-157 are frequently combined in healing protocols. They work through complementary mechanisms: BPC-157 promotes angiogenesis and localized healing, while TB-500 promotes systemic healing and cell migration. They can be mixed in the same syringe for convenience. A common stack is 250-500 mcg BPC-157 with 2-2.5 mg TB-500.

Add 2 mL of bacteriostatic water to a 5 mg vial by directing the stream along the glass wall, allowing the powder to dissolve gently. Do not shake the vial. Each 0.1 mL will contain 250 mcg. For a 2 mg vial with 1 mL of BAC water, each 0.1 mL delivers 200 mcg. Refrigerate after reconstitution and use within 4-6 weeks.

Unlike BPC-157, TB-500 is a systemic peptide and does not need to be injected near the injury site. It works by upregulating actin, which promotes cell migration throughout the body. Standard subcutaneous injection sites such as the abdomen or thigh are appropriate regardless of where the injury is located.

A typical TB-500 cycle lasts 4-12 weeks depending on the condition. The loading phase (2x weekly) usually runs 4-8 weeks, followed by a maintenance phase for as long as needed. Many users take a 4-week break between full loading cycles. For chronic conditions, a lower maintenance dose can be continued long-term.

Community Reviews

All 132 reviews →

No Reviews Yet

Community reviews for TB-500 are being collected. Check back soon.